SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Allstate Life Insurance Co – ‘10-Q’ for 9/30/19 – ‘EX-31.I’

On:  Tuesday, 11/5/19, at 12:36pm ET   ·   For:  9/30/19   ·   Accession #:  352736-19-12   ·   File #:  0-31248

Previous ‘10-Q’:  ‘10-Q’ on 8/7/19 for 6/30/19   ·   Latest ‘10-Q’:  This Filing

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

11/05/19  Allstate Life Insurance Co        10-Q        9/30/19   72:20M

Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q        Quarterly Report                                    HTML   2.63M 
 2: EX-15       Letter re: Unaudited Interim Financial Info         HTML     27K 
 3: EX-31.I     Certification -- §302 - SOA'02                      HTML     34K 
 4: EX-32       Certification -- §906 - SOA'02                      HTML     23K 
26: R1          Document and Entity Information                     HTML     70K 
67: R2          Condensed Consolidated Statements of Operations     HTML    102K 
                and Comprehensive Income (Unaudited)                             
43: R3          Condensed Consolidated Statements of Financial      HTML    146K 
                Position (Unaudited)                                             
15: R4          Condensed Consolidated Statements of Financial      HTML     45K 
                Position (Unaudited) (Parenthetical)                             
25: R5          Condensed Consolidated Statements of Shareholder's  HTML     49K 
                Equity (Unaudited)                                               
66: R6          Condensed Consolidated Statements of Cash Flows     HTML    120K 
                (Unaudited)                                                      
42: R7          General                                             HTML     69K 
14: R8          Supplemental Cash Flow Information                  HTML     41K 
27: R9          Investments                                         HTML    611K 
33: R10         Fair Value of Assets and Liabilities                HTML    894K 
22: R11         Derivative Financial Instruments                    HTML    538K 
45: R12         Reinsurance                                         HTML    102K 
68: R13         Guarantees and Contingent Liabilities               HTML     31K 
35: R14         Other Comprehensive Income                          HTML     84K 
23: R15         General (Tables)                                    HTML     54K 
46: R16         Supplemental Cash Flow Information (Tables)         HTML     39K 
69: R17         Investments (Tables)                                HTML    622K 
32: R18         Fair Value of Assets and Liabilities (Tables)       HTML    868K 
24: R19         Derivative Financial Instruments (Tables)           HTML    568K 
50: R20         Reinsurance (Tables)                                HTML    103K 
59: R21         Other Comprehensive Income (Tables)                 HTML     84K 
36: R22         General (Details)                                   HTML     63K 
10: R23         Supplemental Cash Flow Information - Narrative      HTML     24K 
                (Details)                                                        
51: R24         Supplemental Cash Flow Information - Net change     HTML     33K 
                (Details)                                                        
60: R25         Investments - Fair Values (Details)                 HTML     58K 
37: R26         Investments - Scheduled Maturities (Details)        HTML     57K 
11: R27         Investments - Net Investment Income (Details)       HTML     46K 
52: R28         Investments - Realized Capital Gains and Losses     HTML     39K 
                (Details)                                                        
58: R29         Investments - Realized Capital Gains and Losses by  HTML     33K 
                Transaction Type (Details)                                       
71: R30         Investments - Narrative (Details)                   HTML     57K 
49: R31         Investments - Valuation Changes Included in Net     HTML     29K 
                Income for Investments (Details)                                 
21: R32         Investments - Other-than-temporary impairment       HTML     57K 
                losses (Details)                                                 
31: R33         Investments - Other-than-temporary Losses Included  HTML     36K 
                in AOCI (Details)                                                
70: R34         Investments - Rollforward of Cumulative Credit      HTML     36K 
                Losses (Details)                                                 
48: R35         Investments - Unrealized Net Capital Gains and      HTML     62K 
                Losses (Details)                                                 
19: R36         Investments - Change in Unrealized Net Capital      HTML     43K 
                Gains and Losses (Details)                                       
30: R37         Investments - Portfolio Monitoring (Details)        HTML     92K 
72: R38         Investments - Gross Unrealized Losses by            HTML     41K 
                Unrealized Loss Position and Credit Quality                      
                (Details)                                                        
47: R39         Investments - Carrying Value of Non-impaired Fixed  HTML     56K 
                Rate and Variable Rate Mortgage Loans (Details)                  
62: R40         Investments - Other investments by type (Details)   HTML     32K 
55: R41         Fair Value of Assets and Liabilities - Narrative    HTML     51K 
                (Details)                                                        
13: R42         Fair Value of Assets and Liabilities - Assets and   HTML    170K 
                Liabilities Measured at Fair Value (Details)                     
39: R43         Fair Value of Assets and Liabilities - Level 3      HTML     36K 
                Fair Value Measurement (Details)                                 
61: R44         Fair Value of Assets and Liabilities - Level 3      HTML    152K 
                Assets and Liabilities (Details)                                 
54: R45         Fair Value of Assets and Liabilities - Gains and    HTML     47K 
                Losses included in Net Income for Level 3                        
                (Details)                                                        
12: R46         Fair Value of Assets and Liabilities - Carrying     HTML     50K 
                Values and Fair Value Estimates of Financial                     
                Instruments (Details)                                            
38: R47         Derivative Financial Instruments - Narrative        HTML     46K 
                (Details)                                                        
63: R48         Derivative Financial Instruments - Volume and Fair  HTML    136K 
                Value Positions of Derivative Instruments                        
                (Details)                                                        
53: R49         Derivative Financial Instruments - Gross and Net    HTML     69K 
                Amounts Derivatives (Details)                                    
40: R50         Derivative Financial Instruments - Foreign          HTML     28K 
                Currency Contracts in Cash Flow Hedging                          
                Relationships (Details)                                          
64: R51         Derivative Financial Instruments - Impacts on       HTML     80K 
                Operations and AOCI (Details)                                    
28: R52         Derivative Financial Instruments - Derivative       HTML     35K 
                Netting (Details)                                                
17: R53         Derivative Financial Instruments - Fair Value of    HTML     30K 
                Derivative Instruments (Details)                                 
41: R54         Derivative Financial Instruments - CDS Notional     HTML     44K 
                Amounts by Credit Rating (Details)                               
65: R55         Reinsurance - Effects of Reinsurance (Details)      HTML     62K 
29: R56         Reinsurance - Narrative (Details)                   HTML     27K 
18: R57         Other Comprehensive Income (Details)                HTML     61K 
44: R9999       Uncategorized Items - allstatelife-93019x10q.htm    HTML     24K 
20: XML         IDEA XML File -- Filing Summary                      XML    129K 
34: XML         XBRL Instance -- allstatelife-93019x10q_htm          XML   7.40M 
56: EXCEL       IDEA Workbook of Financial Reports                  XLSX     99K 
 6: EX-101.CAL  XBRL Calculations -- all-20190930_cal                XML    307K 
 7: EX-101.DEF  XBRL Definitions -- all-20190930_def                 XML    872K 
 8: EX-101.LAB  XBRL Labels -- all-20190930_lab                      XML   1.99M 
 9: EX-101.PRE  XBRL Presentations -- all-20190930_pre               XML   1.16M 
 5: EX-101.SCH  XBRL Schema -- all-20190930                          XSD    200K 
16: JSON        XBRL Instance as JSON Data -- MetaLinks              384±   610K 
57: ZIP         XBRL Zipped Folder -- 0000352736-19-000012-xbrl      Zip    399K 


‘EX-31.I’   —   Certification — §302 – SOA’02


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Exhibit  


CERTIFICATIONS
EXHIBIT 31 (i)
I, Steven E. Shebik, certify that:
1. I have reviewed this quarterly report on Form 10-Q of Allstate Life Insurance Company;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2019

Chief Executive Officer






CERTIFICATIONS
EXHIBIT 31 (i)
I, Mario Imbarrato, certify that:            
1. I have reviewed this quarterly report on Form 10-Q of Allstate Life Insurance Company;
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;
4. The registrant’s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
5. The registrant’s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):
a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and
b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 5, 2019

Vice President and Chief Financial Officer
 





Dates Referenced Herein

This ‘10-Q’ Filing    Date    Other Filings
Filed on:11/5/19None on these Dates
For Period end:9/30/19
 List all Filings 
Top
Filing Submission 0000352736-19-000012   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., Apr. 30, 9:19:12.1pm ET